Company Filing History:
Years Active: 2019
Title: John Hazin: Innovator in Binding Molecules
Introduction
John Hazin is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of molecular biology, particularly in the development of binding molecules. His work focuses on innovative solutions that have the potential to impact therapeutic applications.
Latest Patents
John Hazin holds a patent for a binding molecule that specifically targets L1CAM (CD171). This patent, which is recognized for its unique capability to bind to the same L1 epitope as the monoclonal antibody L1-OV52.24, includes detailed specifications regarding the variable parts of the light and heavy chains. The patent also encompasses nucleic acids encoding these binding molecules, their uses, and pharmaceutical compositions that incorporate them. He has 1 patent to his name.
Career Highlights
Hazin is affiliated with the German Cancer Research Center (Deutsches Krebsforschungszentrum), where he contributes to groundbreaking research in cancer biology. His work is instrumental in advancing the understanding of molecular interactions that can lead to new therapeutic strategies.
Collaborations
Throughout his career, John Hazin has collaborated with esteemed colleagues such as Peter Altevogt and Sandra Lüttgau. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.
Conclusion
John Hazin's contributions to the field of binding molecules exemplify the importance of innovation in scientific research. His work not only advances our understanding of molecular interactions but also holds promise for future therapeutic applications.